Kadmon is a biopharmaceutical company that opens, develops and markets transformative treatments for unmet medical needs. It was founded in September 2010. Employees 101.
History
2021: Sanofi bought Kadmon for $1.9 billion
On September 8, 2021, French drugmaker Sanofi said it would buy Kadmon, an American biopharmaceutical company, for $1.9 billion.
Sanofi said it offered $9.50 per share for Kadmon, which is a total stock value of approximately $1.9 billion, and that the boards of directors of both companies unanimously approved the deal. The price offered by Sanofi represents a 79% premium at the time of offer.
 | The acquisition supports the strategy of Sanofi, aimed at further growth of core assets in the field of general-purpose medicines and will immediately add Rezurock (belumit) to the transplant portfolio, the two companies said in a joint statement. |  |
Rezurock is a drug for treating adults and pediatric patients aged 12 years and older with chronic graft-versus-host disease (cGVHD), it was approved in July 2021 by the U.S. Federal Drug Administration (FDA).
The addition of Rezurock will strengthen Sanofi's existing transplant drug portfolio, which includes the Mozobil hematopoietic stem cell mobilizer and the broad-spectrum immunosuppressive drug Thymoglobulin. In 2020, the total sales of these drugs amounted to $626 million.
Sanofi has been in the middle of a five-year reorganization advocated by CEO Paul Hudson since he took the reins in 2019. The strategy to play to win involves increasing Sanofi's focus on vaccines and some specialty areas, such as oncology, while reducing investment in generic drugs, including diabetes and cardiovascular disease, as well as consumer health.
A survey by Jefferies analyst Biren Amin on the eve of the deal foreshadows the success of the new drug. 25 American hematology and transplantology specialists specializing in the treatment of cGVHD suggested that by 2020 Rezurock could take from 9% to 23% of the market share.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |